journal article·2023-08-23

In Situ Construction of Ferrocene-Containing Membrane-Bound Nanofibers for the Redox Control of Cancer Cell Death and Cancer Therapy

Xiangyang Zhang, Yinghao Ding, Zhenghao Zhang, Yiping Ma, Xuan Sun, Ling Wang, Zhimou Yang, Zhi-Wen Hu

Nano Letters· Volume 23· Issue 16
Publisher page

Abstract

Precise manipulation of cancer cell death by harnessing reactive oxygen species (ROS) is a promising strategy to defeat malignant tumors. However, it is quite difficult to produce active ROS with spatial precision and regulate their biological outcomes. We succeed here in selectively generating short-lived and lipid-reactive hydroxyl radicals ( • OH) adjacent to cancer cell membranes, successively eliciting lipid peroxidation and ferroptosis. DiFc-K-pY, a phosphorylated self-assembling precursor that consists of two branched Fc moieties and interacts specifically with epidermal growth factor receptor, can in situ produce membrane-bound nanofibers and enrich ferrocene moieties on cancer cell membranes in response to alkaline phosphatase. Within the acidic tumor microenvironment, DiFc-K-pY nanofibers efficiently convert tumoral H 2 O 2 to active • OH around the target cell membranes via Fenton-like reactions, leading to lipid peroxidation and ferroptosis with good cellular selectivity. Our strategy successfully prevents tumor progression with acceptable biocompatibility through intratumoral administration.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ancient Mediterranean Archaeology and History · Classical Antiquity Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Tianjin Eye Hospital, Tianjin Key Laboratory of Ophthalmology and Visual Science, Nankai University Affiliated Eye Hospital, Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin 300071, P. R. China

Key Laboratory of Cancer Prevention and Therapy, The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, P. R. China

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China

Funding

National Key Research and Development Program of China · Tianjin Municipal Science and Technology Bureau · National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1016/j.immuni.2019.12.01810.1016/j.immuni.2019.12.018 ↗
2. 10.1038/nm.339410.1038/nm.3394 ↗
3. 10.1038/s41565-022-01261-710.1038/s41565-022-01261-7 ↗
4. 10.1038/s42255-020-00317-z10.1038/s42255-020-00317-z ↗
5. 10.1038/s41571-021-00539-410.1038/s41571-021-00539-4 ↗
6. 10.1038/bjc.2016.41210.1038/bjc.2016.412 ↗
7. 10.3390/ijms2105163310.3390/ijms21051633 ↗
8. 10.1016/j.ccell.2023.02.01610.1016/j.ccell.2023.02.016 ↗
9. 10.3389/fonc.2022.86274310.3389/fonc.2022.862743 ↗
10. 10.1038/s41557-019-0328-410.1038/s41557-019-0328-4 ↗
11. 10.1111/cas.1506810.1111/cas.15068 ↗
12. 10.1038/s41568-021-00435-010.1038/s41568-021-00435-0 ↗
13. 10.1038/s41418-021-00859-z10.1038/s41418-021-00859-z ↗
14. 10.1016/j.ccell.2019.04.00210.1016/j.ccell.2019.04.002 ↗
15. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
16. 10.1016/j.chembiol.2018.11.01610.1016/j.chembiol.2018.11.016 ↗
17. 10.1021/acs.chemrev.0c0097710.1021/acs.chemrev.0c00977 ↗
18. 10.1002/anie.20171202710.1002/anie.201712027 ↗
19. 10.1021/acsmaterialslett.2c0107910.1021/acsmaterialslett.2c01079 ↗
20. 10.1002/adfm.20191008510.1002/adfm.201910085 ↗
21. 10.1002/smll.20210136810.1002/smll.202101368 ↗
22. 10.1016/j.chempr.2019.05.02410.1016/j.chempr.2019.05.024 ↗
23. 10.1002/anie.20230382910.1002/anie.202303829 ↗
24. 10.1021/acs.nanolett.1c0207310.1021/acs.nanolett.1c02073 ↗
25. 10.1016/j.actbio.2023.01.05010.1016/j.actbio.2023.01.050 ↗
26. 10.1016/j.cej.2020.12462810.1016/j.cej.2020.124628 ↗
27. 10.1039/D2BM01172G10.1039/D2BM01172G ↗
28. 10.1002/adma.20070197110.1002/adma.200701971 ↗
29. 10.1021/jacs.2c0549110.1021/jacs.2c05491 ↗
30. 10.1002/adfm.20220696910.1002/adfm.202206969 ↗
31. 10.1021/jacs.2c1182310.1021/jacs.2c11823 ↗
32. 10.1021/acs.langmuir.6b0177210.1021/acs.langmuir.6b01772 ↗
33. 10.1021/acs.biomac.2c0090110.1021/acs.biomac.2c00901 ↗
34. 10.1007/s00726-017-2482-610.1007/s00726-017-2482-6 ↗
35. 10.1016/j.jbiotec.2017.01.02010.1016/j.jbiotec.2017.01.020 ↗
36. 10.1002/admi.20190108210.1002/admi.201901082 ↗
37. 10.1074/jbc.M116.75717910.1074/jbc.M116.757179 ↗
38. 10.1021/acsmacrolett.2c0063010.1021/acsmacrolett.2c00630 ↗
39. 10.1021/jacs.8b0464110.1021/jacs.8b04641 ↗
40. 10.1002/adma.20200003810.1002/adma.202000038 ↗
41. 10.1074/jbc.M20926420010.1074/jbc.M209264200 ↗
42. 10.1021/acsomega.2c0228510.1021/acsomega.2c02285 ↗
43. 10.1038/s41420-021-00599-610.1038/s41420-021-00599-6 ↗
44. 10.1016/j.celrep.2020.02.04910.1016/j.celrep.2020.02.049 ↗
45. 10.1074/jbc.M21254920010.1074/jbc.M212549200 ↗
46. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
47. 10.1038/s41420-021-00599-610.1038/s41420-021-00599-6 ↗
48. 10.1038/s41392-019-0073-610.1038/s41392-019-0073-6 ↗
49. 10.1038/s41418-020-00691-x10.1038/s41418-020-00691-x ↗
50. 10.1038/s41420-022-01199-810.1038/s41420-022-01199-8 ↗